Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 30, 2015 10:03 PM ET

Life Sciences Tools and Services

Company Overview of Abbott Molecular Inc.

Company Overview

Abbott Molecular Inc. provides molecular diagnostics equipment and reagents to physicians, individuals, molecular laboratories, and companies in the United States and internationally. The company offers critical information based on the early detection of pathogens and subtle changes in patients' genes and chromosomes; and m2000 system that enables clinical laboratories to automate complex and manual steps associated with molecular diagnostic testing. It also provides various products in the areas of genetics, infectious diseases, oncology, transplantation, analyte specific reagents, instrumentation and automation, and general purpose reagents. In addition, the company offers accessories, in...

1300 East Touhy Avenue

Des Plaines, IL 60018-3315

United States

Founded in 1989

133 Employees

Phone:

224-361-7000

Fax:

224-361-7008

Key Executives for Abbott Molecular Inc.

President of European Operations
Chief Medical Officer and Vice President of Research & Development
Vice President, Secretary and General Counsel
Age: 62
Compensation as of Fiscal Year 2015.

Abbott Molecular Inc. Key Developments

Idera Pharmaceuticals, Inc. Enters into an Agreement with Abbott for the Development of an in Vitro Companion Diagnostic Test

Idera Pharmaceuticals, Inc. announced that it has entered into an agreement with Abbott for the development of an in vitro companion diagnostic test for use in Idera’s clinical development programs to treat certain genetically defined forms of B-cell lymphoma with IMO-8400. Under the agreement, Abbott will develop a test utilizing polymerase chain reaction (PCR) technology to identify the presence of the MYD88 L265P oncogenic mutation in tumor biopsy samples with high sensitivity and specificity. This mutation, which can be identified in approximately 90% of patients with Waldenström’s macroglobulinemia and approximately 30% of patients with the ABC sub-type of diffuse large B-cell lymphoma, plays a key role in activating the Toll-like receptor (TLR) pathways targeted by Idera’s lead drug candidate, IMO-8400.

Similar Private Companies By Industry

Company Name Region
QS Pharma, LLC United States
Oncotherapeutics, Inc. United States
Fluorous Technologies, Inc. United States
SensiQ Technologies, Inc. United States
AnaSpec, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Abbott Molecular Inc., please visit www.abbottmolecular.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.